Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT01014767
- Locations
- 🇳🇿
Christchurch Hospital, Christchurch, New Zealand
🇺🇸Tufts Medical Center, Boston, Massachusetts, United States
🇭🇺Semmelweis University, Budapest, Hungary
Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-11-16
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Target Recruit Count
- 41
- Registration Number
- NCT01013805
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00954512
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
- Conditions
- Interventions
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 140
- Registration Number
- NCT00941499
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
- Conditions
- Interventions
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00941655
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT00940303
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
- Conditions
- Interventions
- First Posted Date
- 2009-07-03
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 70
- Registration Number
- NCT00932438
- Locations
- 🇺🇸
Northside Hospital/GA Cancer Specialists, Atlanta, Georgia, United States
🇦🇷Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
🇺🇸Clearview Cancer Center, Huntsville, Alabama, United States
Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 101
- Registration Number
- NCT00889343
- Locations
- 🇩🇪
Friedrich-Ebert-Krankenhaus Neumünster, Klinik für Hämatologie, Onkologie und Nephrologie, Neumünster, Schleswig-Holstein, Germany
🇩🇪Hämatologisch-onkologische Praxis Dr. med. Peter Schmidt, Neunkirchen, Saarland, Germany
🇩🇪Medizinisches Versorgungszentrum am Siloah St. Trudpert Klinikum, Pforzheim, Baden-Würtemberg, Germany
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT00878254
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT00865189
- Locations
- 🇫🇷
ICO Paul Papin; Oncologie Medicale., Angers, France
🇫🇷HOPITAL JEAN MINJOZ; Oncologie, Besancon, France
🇫🇷Hopital Saint Andre; Département de Radiothérapie Et D'Oncologie Médicale, Bordeaux, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.